

Case Number:	CM14-0179352		
Date Assigned:	11/03/2014	Date of Injury:	07/05/1995
Decision Date:	12/10/2014	UR Denial Date:	10/07/2014
Priority:	Standard	Application Received:	10/28/2014

HOW THE IMR FINAL DETERMINATION WAS MADE

MAXIMUS Federal Services sent the complete case file to an expert reviewer. He/she has no affiliation with the employer, employee, providers or the claims administrator. The expert reviewer is Board Certified in Physical Medicine and Rehabilitation, has a subspecialty in Pain Medicine and is licensed to practice in California. He/she has been in active clinical practice for more than five years and is currently working at least 24 hours a week in active practice. The expert reviewer was selected based on his/her clinical experience, education, background, and expertise in the same or similar specialties that evaluate and/or treat the medical condition and disputed items/services. He/she is familiar with governing laws and regulations, including the strength of evidence hierarchy that applies to Independent Medical Review determinations.

CLINICAL CASE SUMMARY

The expert reviewer developed the following clinical case summary based on a review of the case file, including all medical records:

This is a patient with a date of injury of July 5, 1995. A utilization review determination dated October 7, 2014 recommends non-certification of Lidoderm. A progress report dated April 16, 2014 identifies subjective complaints of chronic low back pain radiating into both legs. The patient's pain medications reduces pain when doing physical activity. Lunesta helps the patient fall asleep. With this regimen, the patient is able to do activities of daily living. Objective examination findings revealed tenderness and limited range of motion in the lumbar spine. Diagnoses include chronic low back pain status post decompression, lumbar degenerative disc disease, lumbar radiculopathy, and depression secondary to chronic pain. The treatment plan recommends refilling the patient's medications, continuing to use a lumbar brace, continuing to use a tens unit, continuing a home exercise program, and review of an MRI report. A progress report dated September 30, 2014 states that Lunesta helps the patient fall asleep. The notes do not indicate how much the Lidoderm improves the patient's pain and function or how it is being used.

IMR ISSUES, DECISIONS AND RATIONALES

The Final Determination was based on decisions for the disputed items/services set forth below:

Lidoderm Patch 5% #30: Upheld

Claims Administrator guideline: Decision based on MTUS ACOEM Page(s): 49. Decision based on Non-MTUS Citation Official Disability Guidelines (ODG), Lidoderm (Lidocaine Patch)

MAXIMUS guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Page(s): 112.

Decision rationale: Regarding request for topical Lidoderm, Chronic Pain Medical Treatment Guidelines recommend the use of topical lidocaine for localized peripheral pain after there has been evidence of a trial of the 1st line therapy such as tri-cyclic antidepressants, SNRIs, or antiepileptic drugs. Within the documentation available for review, there is no indication that the patient has failed first-line therapy recommendations. Additionally, there is no documentation of analgesic effect or objective functional improvement as a result of the currently prescribed Lidoderm. Finally, there is no documentation of localized peripheral pain as recommended by guidelines. As such, the currently requested Lidoderm is not medically necessary.